Kbc Group Nv Cti Biopharma Corp Transaction History

Kbc Group Nv

  • $33.1 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 03, 2022
SELL
$1.44 - $2.86 $20,628 - $40,969
-14,325 Closed
0 $0
Q3 2021

Nov 10, 2021
SELL
$2.25 - $3.18 $35,149 - $49,677
-15,622 Reduced 52.17%
14,325 $42,000
Q2 2021

Aug 11, 2021
BUY
$2.16 - $2.62 $64,685 - $78,461
29,947 New
29,947 $75,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email